British data analytics firm Sensyne Health has revealed it is unlikely to be able to continue trading beyond February 2022 without securing emergency funding.
In November, the Oxford-based firm announced the commencement of a formal sale process (FSP), which led to discussions with corporates…
Source: Healthcareitnews.com and Read More